MedTrace Logo

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

NCT05110846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2026-02-05

No results posted yet for this study

Summary

A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

Placebo

Participants self-injected once-daily subcutaneous volume- and regimen-matched placebo for 26 weeks.

DRUG

CT-868

Participants self-injected once-daily subcutaneous CT-868 for 26 weeks according to the randomized dose and regimen.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Carmot Therapeutics, Inc., a Member of the Roche Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2023-02-28
Completion
2023-02-28
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05110846 on ClinicalTrials.gov